A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3 Clinical Trial

Official title: A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies

Status Completed

Clinical Trial Summary

The study will determine the maximum tolerated dose and thus the recommended phase II dose and schedule of the compound and characterize the safety.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3
• Advanced Solid Tumors With FGFR1 Amplication
• Advanced Solid Tumors With FGFR2 Amplication
• Advanced Solid Tumors With FGFR3 Mutation
• Bladder Cancer With FGFR3 Mutation or Fusion
• Neoplasms
• Squamous Lung Cancer With FGFR1 Amplification
• Urinary Bladder Neoplasms

• NCT number: NCT01004224
• Study type: Interventional
• Source: Novartis
• Status: Completed
• Phase: Phase 1
• Start date: December 11, 2009
• Completion date: October 8, 2018